<?xml version="1.0" encoding="UTF-8"?>
<p id="p0105">Use of recombinant IFN-α or IFN-β as a treatment in SARS, MERS, and now COVID-19 has been a subject of debate (
 <xref rid="bib52" ref-type="bibr">Sallard et al., 2020</xref>). IFN-I was identified as a promising therapeutic candidate in SARS and MERS based on numerous 
 <italic>in vitro</italic> and 
 <italic>in vivo</italic> studies (
 <xref rid="bib63" ref-type="bibr">Stockman et al., 2006</xref>). In marmosets, treatment of MERS-CoV-infected animals with IFN-β1b reduced viral load and lung pathology (
 <xref rid="bib7" ref-type="bibr">Chan et al., 2015</xref>). In a mouse model of MERS-CoV infection, although treatment with IFN-β in combination with lopinavir-ritonavir did not significantly reduce lung pathology, it improved pulmonary function (
 <xref rid="bib58" ref-type="bibr">Sheahan et al., 2020</xref>). Administration of IFN-α2b with ribavirin to MERS-CoV-infected macaques resulted in better viral control and clinical outcomes (
 <xref rid="bib16" ref-type="bibr">Falzarano et al., 2013</xref>). Animal studies of SARS-CoV infection showed similar efficacy. Prophylactic treatment of macaques with IFN-α prior to SARS-CoV infection greatly reduced viral replication and pulmonary damage (
 <xref rid="bib23" ref-type="bibr">Haagmans et al., 2004</xref>).
</p>
